Flixotide

Fluticasone propionate

Adults & adolescents ≥16 yr Prophylactic management: Mild asthma Patients requiring intermittent symptomatic bronchodilator asthma medication on more than an occasional basis. Moderate asthma Patients requiring regular asthma medication & patients w/ unstable or worsening asthma on currently available prophylactic therapy or bronchodilator alone. Severe asthma Patients w/ severe chronic asthma. On introduction of inhaled fluticasone propionate, many patients who are dependent on systemic corticosteroids for adequate control of symptoms may be able to reduce significantly or to eliminate their requirement for oral corticosteroids. Childn ≥12 mth Any child who requires preventive asthma medication, including patients not controlled on currently available prophylactic medication.

Adult & adolescent ≥16 yr 100-1,000 mcg bd. Mild asthma 100-250 mcg bd. Moderate asthma 250-500 mcg bd. Severe asthma 500-1,000 mcg bd. Childn 4 to <16 yr 50-200 mcg bd, 12 mth to 4 yr 100 mcg bd via paed spacer device w/ face mask.

Hypersensitivity.

Not for use in acute asthma attacks. Do not stop treatment abruptly. Reassess patient's therapy plan in case of deterioration of asthma control. Consider very rare reports of increases in blood glucose levels when prescribing to patients w/ history of DM. Caution in patients w/ active or quiescent pulmonary TB. Immediately discontinue treatment in case of paradoxical bronchospasm. Possible systemic effects include Cushing's syndrome, Cushingoid features, depression of hypothalamic-pituitary-adrenal axis, reduction of bone density, retardation of growth rate, cataract, glaucoma & central serous chorioretinopathy. Titrate down to the lowest dose that effectively controls asthma to minimise systemic effects. Risk of impaired adrenal reserve for a considerable time after transferring to inhaled Flixotide in medical/surgical emergency patients w/ past medication history of high-dose inhaled steroids &/or intermittent treatment w/ oral steroids. Regularly monitor adrenocortical function in patients transferring from oral to inhaled therapy. Replacement of systemic w/ inhaled therapy may unmask allergies previously controlled by systemic drug. Avoid concomitant use w/ ritonavir. Consider administration during pregnancy & lactation only if expected benefit to mother is greater than any possible risk to foetus/child. Monitor growth of paed patients.

Candidiasis (thrush) of the mouth & throat. Contusions; hoarseness.

Greatly increased plasma conc w/ ritonavir (highly potent CYP3A4 inhibitor). Potential for increased systemic exposure w/ potent CYP3A4 inhibitors (eg, ketoconazole).

Antiasthmatic & COPD Preparations

R03BA05 - fluticasone ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids.

P₁S₁S₃